KRT7 and teratoma: This panel should incorporate anti-CK7, anti-CK20, anti-PAX8, and anti-SATB2 antibodies.39 However, in Group 2 (teratomas), SATB2 was not positive in all tumors and PAX8 expression was focal/weak in one case.